Crispr Therapeutics AG (CRSP)
Healthcare
Biotechnology
49.60 $
+3.3%
vs. previous close
Closing price · As of: 3. Aug 2026
Crispr Therapeutics AG (CRSP) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -109 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -133 | -40 | -96 | 110 | -96 | -107 | -50 | -54 | -114 | -85 | -93 | -109 | -400 | |
| 5.0 | 4.9 | 4.9 | 4.8 | 4.8 | 4.7 | 4.8 | 4.7 | 4.6 | 4.4 | 5.7 | 4.3 | 19 | |
| 22 | 20 | 18 | 19 | 24 | 22 | 22 | 20 | 18 | 17 | 18 | 16 | 69 | |
| 19 | – | – | – | – | – | – | – | – | – | – | – | – | |
| -79 | 53 | -204 | 210 | 10 | -40 | -24 | 55 | -17 | 11 | 23 | -15 | 1.6 | |
| 3.6 | 2.1 | 0.7 | 0.7 | 0.7 | 0.2 | 0.3 | 0.2 | 0.1 | 0.1 | 0.5 | 0.5 | 1.2 | |
| 217 | 121 | -81 | -98 | -127 | -162 | 106 | -20 | 70 | -119 | 37 | -411 | -423 | |
| – | – | – | – | -0.5 | 0.5 | – | – | 71 | 71 | – | – | – | |
| 17 | 1.6 | 39 | 306 | -0.5 | 9.6 | 17 | 11 | 2.3 | 297 | 116 | 592 | 1,007 | |
| 100 | 83 | -138 | 318 | -223 | -259 | 73 | -63 | -42 | 93 | 61 | 69 | 181 | |
| -137 | -42 | -97 | 109 | -96 | -107 | -50 | -54 | -114 | -85 | -93 | -109 | -401 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.